Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2015

Open Access 01-12-2015 | Meeting abstract

Performance on functional capacity tests and level of physical activity in women with metabolic syndrome

Authors: Caroline Hellen Rampazzo Alves, Shirley Aparecida Fabris de Souza, Nathália Caroline Valentini de Azevedo, Décio Sabbatini Barbosa, Danielle Venturini, Alessandra M Okino

Published in: Diabetology & Metabolic Syndrome | Special Issue 1/2015

Login to get access

Excerpt

Metabolic Syndrome (MetS) is a condition associated an increased risk for type 2 diabetes and heart disease as hypertension, high triglyceride levels, low HDL cholesterol levels, and above-normal blood glucose levels. …
Metadata
Title
Performance on functional capacity tests and level of physical activity in women with metabolic syndrome
Authors
Caroline Hellen Rampazzo Alves
Shirley Aparecida Fabris de Souza
Nathália Caroline Valentini de Azevedo
Décio Sabbatini Barbosa
Danielle Venturini
Alessandra M Okino
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue Special Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-7-S1-A233

Other articles of this Special Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine